Brain

New Peer-Reviewed Study Shows That Olleyes VisuALL VRP is Comparable to HVF and Offers Valuable Supplement to Standard Automated Perimetry for Pediatric Patients

Study completed at Duke University shows that the VisuALL is suitable substitute for HVF when testing pediatric patients.SUMMIT, NJ /...

ADvantage Therapeutics Has Commenced Enrollment for Its Phase 2b Clinical Trial of AD04™ for Treatment of Alzheimer’s Disease

MIAMI, Nov. 27, 2023 (GLOBE NEWSWIRE) -- ADvantage Therapeutics, Inc. (“ADvantage” or “the Company”), a pioneer in developing therapies for...

GE HealthCare Showcases More Than 40 Innovations, Including AI-Enabled Imaging Technology Solutions Designed for Precision Care at RSNA23

Booth (#7326) will highlight new product introductions, key innovations, and AI-enabled advancements from the company’s comprehensive portfolio of Imaging, Ultrasound,...

Scilex Holding Company Announces Market Research Results with Neurologists, Headache Specialists, and Primary Care Physicians Demonstrating Potential High Unmet Needs In Treating Acute Migraine Targeted By ELYXYB® with Potential Advantages Compared to Calcitonin Gene-Related Peptide (CGRP) Products and Triptan Therapy

CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy

Data presented at the Society of NeuroOncology (SNO) 28th Annual MeetingBerubicin currently being evaluated in an ongoing potentially pivotal study...

Algernon Pharmaceuticals Announces LOI for the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position

VANCOUVER, British Columbia, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB:...

error: Content is protected !!